ATE486055T1 - Neue verbindungen, ihre herstellung und verwendung - Google Patents
Neue verbindungen, ihre herstellung und verwendungInfo
- Publication number
- ATE486055T1 ATE486055T1 AT05747983T AT05747983T ATE486055T1 AT E486055 T1 ATE486055 T1 AT E486055T1 AT 05747983 T AT05747983 T AT 05747983T AT 05747983 T AT05747983 T AT 05747983T AT E486055 T1 ATE486055 T1 AT E486055T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- diabetes
- pharmaceutical compositions
- type
- production
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 108010015181 PPAR delta Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400719 | 2004-05-05 | ||
| PCT/EP2005/052014 WO2005105726A1 (en) | 2004-05-05 | 2005-05-03 | Novel compounds, their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE486055T1 true ATE486055T1 (de) | 2010-11-15 |
Family
ID=34968773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05747983T ATE486055T1 (de) | 2004-05-05 | 2005-05-03 | Neue verbindungen, ihre herstellung und verwendung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7968723B2 (de) |
| EP (1) | EP1745003B1 (de) |
| JP (1) | JP2007536343A (de) |
| AT (1) | ATE486055T1 (de) |
| DE (1) | DE602005024384D1 (de) |
| ES (1) | ES2352085T3 (de) |
| WO (1) | WO2005105726A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745445B2 (en) * | 2004-05-14 | 2010-06-29 | Irm Llc | Compounds and compositions as PPAR modulators |
| US7622491B2 (en) * | 2004-08-13 | 2009-11-24 | Metabolex Inc. | Modulators of PPAR and methods of their preparation |
| AU2006265172B2 (en) | 2005-06-30 | 2011-09-15 | Vtv Therapeutics Llc | Phenoxy acetic acids as PPAR delta activators |
| CA2645719A1 (en) * | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
| JP2012171911A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Ｐｐａｒ活性化剤 |
| CN112759515B (zh) * | 2020-12-28 | 2023-06-13 | 广东药科大学 | 一种新型FFA1和PPARα/γ/δ四重激动剂、其制备方法及其作为药物的用途 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4920132A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US5324743A (en) | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
| GB2279659B (en) * | 1993-07-05 | 1998-04-22 | Merck Patent Gmbh | Liquid crystalline material |
| JP2002503202A (ja) | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | 抗糖尿病薬 |
| ATE236137T1 (de) | 1996-02-02 | 2003-04-15 | Merck & Co Inc | Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit |
| CA2245524A1 (en) | 1996-02-02 | 1997-08-07 | Wei Han | Antidiabetic agents |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| CA2244831A1 (en) | 1996-02-02 | 1997-08-07 | John T. Olson | Method of treating diabetes and related disease states |
| AU719663B2 (en) | 1996-12-23 | 2000-05-11 | Merck & Co., Inc. | Antidiabetic agents |
| ES2320181T3 (es) | 1997-07-24 | 2009-05-19 | Astellas Pharma Inc. | Composiciones farmaceuticas que tienen un efecto reductor del colesterol. |
| HUP0101022A1 (hu) | 1997-10-17 | 2001-10-28 | Aventis Pharmaceuticals Products Inc. | Kinolinszármazékok gyógyászati alkalmazása |
| JP2003500432A (ja) | 1999-06-01 | 2003-01-07 | ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター | ジフェニルエーテル誘導体を用いて脱毛症を処置する方法 |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| WO2001025226A1 (en) | 1999-10-05 | 2001-04-12 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
| AU1303301A (en) | 1999-11-10 | 2001-06-06 | Takeda Chemical Industries Ltd. | Body weight gain inhibitors |
| HUP0204449A3 (en) | 1999-11-11 | 2006-02-28 | Lilly Co Eli | Oncolytic combinations for the treatment of cancer, containing 2',2'-difluoronucleoside and leukotriene antagonist as active ingredients |
| US6569901B2 (en) | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
| WO2001060807A1 (en) | 2000-02-18 | 2001-08-23 | Merck & Co. Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| JP2004500389A (ja) | 2000-03-09 | 2004-01-08 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｐｐａｒメディエーターの治療での使用 |
| US6448293B1 (en) | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
| JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| EP1310494B1 (de) | 2000-08-11 | 2012-01-25 | Nippon Chemiphar Co., Ltd. | Ppar-delta aktivatoren |
| US6630504B2 (en) | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
| GB0024361D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| WO2002046154A1 (fr) | 2000-12-05 | 2002-06-13 | Nippon Chemiphar Co., Ltd. | Activateurs $g(d) de recepteur active par un proliferateur du peroxysome |
| GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031103D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| ATE433964T1 (de) | 2000-12-28 | 2009-07-15 | Takeda Pharmaceutical | Alkansäurederivate, verfahren zu deren herstellung und deren verwendung |
| EP1357914A2 (de) | 2001-02-02 | 2003-11-05 | SmithKline Beecham Corporation | Verfahren zur behandlung von ppar vermittelten krankheiten |
| WO2002076957A1 (en) | 2001-03-23 | 2002-10-03 | Nippon Chemiphar Co.,Ltd. | Activator for peroxisome proliferator-activated receptor |
| US7253178B2 (en) | 2001-03-28 | 2007-08-07 | Eisai Co., Ltd. | Carboxylic acids |
| JPWO2002080899A1 (ja) | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | 消化器疾患治療剤 |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| EP1394147A4 (de) | 2001-06-04 | 2007-10-24 | Eisai R&D Man Co Ltd | Carbonsäurederivat und eine ein salz oder ein ester davon enthaltende medizin |
| FR2826574B1 (fr) | 2001-06-29 | 2005-08-26 | Oreal | Compositions contenant un derive d'hydroxydiphenyl ether inhibant le developpement des odeurs corporelles |
| IL160304A0 (en) | 2001-08-10 | 2004-07-25 | Nippon Chemiphar Co | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR delta |
| US7371777B2 (en) | 2001-08-17 | 2008-05-13 | Eisai Co., Ltd. | Cyclic compound and PPAR agonist |
| US6869975B2 (en) | 2001-09-14 | 2005-03-22 | Tularik Inc. | Linked biaryl compounds |
| PT1445258E (pt) | 2001-10-12 | 2009-07-02 | Nippon Chemiphar Co | Activador para o receptor delta activado por proliferador de peroxissoma |
| HUP0401837A2 (hu) | 2001-10-17 | 2004-12-28 | Novo Nordisk A/S | Dikarbonsavszármazékok, előállításuk és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| DE10151390A1 (de) | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| JP2003171275A (ja) | 2001-12-11 | 2003-06-17 | Sumitomo Pharmaceut Co Ltd | ＰＰＡＲδアゴニスト |
| ATE369855T1 (de) | 2002-02-25 | 2007-09-15 | Lilly Co Eli | Modulatoren von peroxisome proliferator- aktivierten rezeptoren |
| JP4383177B2 (ja) | 2002-03-01 | 2009-12-16 | スミスクライン ビーチャム コーポレーション | ｈＰＰＡＲ活性化剤 |
| US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
| US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| US20030207924A1 (en) | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| DE10222034A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Tetrahydroisochinolin-Derivate |
| GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| GB0214254D0 (en) | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| DE10229777A1 (de) | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
| WO2004007439A1 (ja) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | ビアリール誘導体 |
| BR0314335A (pt) | 2002-09-05 | 2005-07-26 | Novo Nordisk As | Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade |
| EP1578716A1 (de) * | 2002-12-20 | 2005-09-28 | Novo Nordisk A/S | Dicarbonsäurederivate alsppar-agonisten |
| US7816385B2 (en) | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| AU2003296404A1 (en) | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heterocyclic ppar modulators |
| DE10300099A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Indol-Phenylsulfonamid-Derivate |
| CN1747936A (zh) * | 2003-02-12 | 2006-03-15 | 特兰斯泰克制药公司 | 作为治疗试剂的取代吡咯衍生物 |
| CN1751037A (zh) | 2003-02-14 | 2006-03-22 | 伊莱利利公司 | 作为ppar调节剂的磺酰胺衍生物 |
| US20070105959A1 (en) | 2003-03-11 | 2007-05-10 | Shinya Kusuda | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient |
| TW200510279A (en) | 2003-03-13 | 2005-03-16 | Ono Pharmaceutical Co | Iminoether derivative compound and medicament containing same as active ingredient |
| CA2521175A1 (en) | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| DE602004002394T2 (de) | 2003-04-17 | 2007-09-13 | Kalypsys, Inc., San Diego | (3-{3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino]-propoxy}-phenyl)-essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen |
| MXPA05011536A (es) | 2003-04-30 | 2006-01-23 | Inst For Pharm Discovery Inc | Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b. |
| ES2299906T3 (es) * | 2003-11-25 | 2008-06-01 | Eli Lilly And Company | Moduladores de receptores activados por proliferadores de peroxisomas. |
| KR20060134191A (ko) | 2004-04-01 | 2006-12-27 | 아벤티스 파마슈티칼스 인크. | 미엘린 탈락 질환을 치료하기 위한 ｐｐｒ 델타 효능제의용도 |
| DE602005027677D1 (de) | 2004-04-01 | 2011-06-09 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung |
| RU2365589C2 (ru) | 2004-04-01 | 2009-08-27 | Авентис Фармасьютикалз Инк. | 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта, фармацевтические композиции на их основе и способ лечения |
| US7745445B2 (en) | 2004-05-14 | 2010-06-29 | Irm Llc | Compounds and compositions as PPAR modulators |
| AU2006265172B2 (en) | 2005-06-30 | 2011-09-15 | Vtv Therapeutics Llc | Phenoxy acetic acids as PPAR delta activators |
| CA2645719A1 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
-
2005
- 2005-05-03 US US11/579,712 patent/US7968723B2/en not_active Expired - Fee Related
- 2005-05-03 DE DE602005024384T patent/DE602005024384D1/de not_active Expired - Lifetime
- 2005-05-03 WO PCT/EP2005/052014 patent/WO2005105726A1/en not_active Ceased
- 2005-05-03 JP JP2007512189A patent/JP2007536343A/ja not_active Withdrawn
- 2005-05-03 ES ES05747983T patent/ES2352085T3/es not_active Expired - Lifetime
- 2005-05-03 AT AT05747983T patent/ATE486055T1/de not_active IP Right Cessation
- 2005-05-03 EP EP05747983A patent/EP1745003B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005024384D1 (de) | 2010-12-09 |
| US20090209588A1 (en) | 2009-08-20 |
| EP1745003B1 (de) | 2010-10-27 |
| WO2005105726A1 (en) | 2005-11-10 |
| JP2007536343A (ja) | 2007-12-13 |
| US7968723B2 (en) | 2011-06-28 |
| ES2352085T3 (es) | 2011-02-15 |
| EP1745003A1 (de) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008024390A3 (en) | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders | |
| ATE528300T1 (de) | Bizyklische verbindungen und ihre verwendung als antidiabetika | |
| WO2010036613A8 (en) | Novel cyclic benzimidazole derivatives useful anti-diabetic agents | |
| NO20035526D0 (no) | Forbindelser for behandling av metabolske forstyrrelser | |
| WO2006127503A3 (en) | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | |
| EA200870470A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
| CY1114660T1 (el) | ΠΑΡΑΓΩΓΑ 2-ΑΔΑΜΑΝΤΥΛΟΥΡΙΑΣ ΩΣ ΕΚΛΕΚΤΙΚΟΙ ΑΝΑΣΤΟΛΕΙΣ 11β-HSD1 | |
| ATE386715T1 (de) | Modulatoren des peroxisomproliferatoraktivierten rezeptors | |
| ATE555081T1 (de) | Adamantyl-derivate als inhibitoren des 11-beta- hydroxysteroid-dehydrogenase-1-enzyms | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| EA201200968A1 (ru) | Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин | |
| RU2010120808A (ru) | Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение | |
| DE602006019880D1 (de) | Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten | |
| BR0213253A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento de condições mediadas por receptores nucleares e de diabetes tipo i, diabetes tipo ii, dislipidemia, sìndrome x (incluindo a sìndrome metabólica, i.e. tolerância prejudicada à glicose, resistência á insulina, hipertrigliceridemia e/ou ou obesidade), doenças cardiovasculares (incluindo aterosclerose) ou hipercolesteremia | |
| DE502005010170D1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
| WO2007056771A3 (en) | Compounds for the treatment of metabolic disorders | |
| EA200601869A1 (ru) | Карбоновые кислоты | |
| EP1948161A4 (de) | Verfahren zur prävention und behandlung von ppar-vermittelten zuständen mit macelignan | |
| ATE486055T1 (de) | Neue verbindungen, ihre herstellung und verwendung | |
| WO2004037776A3 (en) | Novel compounds and their use as prar-modulators | |
| EA200601120A1 (ru) | N-арилпиперидинзамещённые бифинилкарбоксамиды в качестве ингибиторов аполипопротеина в | |
| WO2006014262A3 (en) | Indoles having anti-diabetic activity | |
| ATE515494T1 (de) | Neue verbindungen, deren herstellung und verwendung | |
| DE60332860D1 (de) | Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen | |
| ATE486838T1 (de) | Neue verbindungen, ihre herstellung und verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |